Browsing by Author Linton, Anthony

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 10 of 10
Issue DateTitleAuthor(s)Citation
2014Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South WalesClarke, Stephen; Kao, Steven; Linton, Anthony; Pavlakis, Nick; Soeberg, Matthew; van Zandwijk, Nico; Vardy, Janette; O’Connell, R; Northern Clinical School: Kolling Institute; Concord Clinical School: Medicine; Concord Clinical School: Medicine; Northern Clinical School: Medicine; School of Public Health: Public Health; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: MedicineFactors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales, British Journal of Cancer, vol.111, 9, 2014,pp 1860-1869
2017Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomesKao, Steven; Linton, Anthony; van Zandwijk, Nico; Broome, R; Soeberg, Matthew; Central Clinical School: Medicine; Concord Clinical School: Medicine; Concord Clinical School: MedicineGeographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes, Respirology, vol.22, 5, 2017,pp 978-985
2013Glasgow Prognostic Score As a Prognostic Factor in Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel-Based ChemotherapyClarke, Stephen; Linton, Anthony; Vardy, Janette; Galsky, Matthew; Pond, G; Sonpavde, Guru; Concord Clinical School: Medicine; Concord Clinical School: Medicine; Concord Clinical School: MedicineGlasgow Prognostic Score As a Prognostic Factor in Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel-Based Chemotherapy, Clinical Genitourinary Cancer, vol.11, 4, 2013,pp 423-430
2013Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: Trends in Australia and a literature reviewClarke, Stephen; Kao, Steven; Linton, Anthony; van Zandwijk, Nico; Vardy, Janette; Klebe, Sonja; Concord Clinical School: Medicine; Concord Clinical School: Medicine; Concord Clinical School: Medicine; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: MedicineImmunohistochemistry in the diagnosis of malignant pleural mesothelioma: Trends in Australia and a literature review, Asia Pacific Journal of Clinical Oncology, vol.9, 3, 2013,pp 273-279
2015miR-193a-3p is a potential tumor suppressor in malignant pleural mesotheliomaCooper, Wendy Anne; Edelman, John (James); Hanh, Jacky; Kao, Steven; Kirschner, Michaela; Linton, Anthony; Reid, Glen; Vallely, Michael; van Zandwijk, Nico; Amaro-Mugridge, Nancy; Brahmbhatt, Himanshu; Cheng, YuenYee; Klebe, Sonja; Lin, Ruby C. Y.; MacDiarmid, Jennifer; McCaughan, Brian; Weiss, Jocelyn; Williams, Marissa; Wright, Casey; Central Clinical School: Medicine; Central Clinical School: Surgery; Concord Clinical School: Asbestos Disease Research Institute; Concord Clinical School: Medicine; Concord Clinical School: Medicine; Concord Clinical School: Medicine; Concord Clinical School: Medicine; Central Clinical School: Surgery; Concord Clinical School: ANZAC Research InstitutemiR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma, Oncotarget, vol.6, 27, 2015,pp 23480-23495
2015MiR-Score: A novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesotheliomaArmstrong, Nicola Joy; Cheng, Yuen Yee; Kao, Steven; Kirschner, Michaela; Lin, Ruby; Linton, Anthony; McCaughan, Brian; Reid, Glen; van Zandwijk, Nico; Klebe, Sonja; Mathematics & Statistics; Concord Clinical School: Asbestos Disease Research Institute; Concord Clinical School: Medicine; Concord Clinical School: Medicine; Molecular Bioscience; Concord Clinical School: Medicine; Central Clinical School: Surgery; Concord Clinical School: Medicine; Concord Clinical School: ANZAC Research InstituteMiR-Score: A novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma, Molecular Oncology, vol.9, N/A, 2015,pp 715-726
2014An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesotheliomaCheng, Yuen Yee; Gattani, S; Kao, Steven; Kirschner, Michaela; Linton, Anthony; McCaughan, Brian; Reid, Glen; Srikaran, Subothini; van Zandwijk, Nico; Griggs, Kim; Klebe, Sonja; Concord Clinical School: Asbestos Disease Research Institute; Concord Clinical School: Asbestos Disease Research Institute; Concord Clinical School: Medicine; Concord Clinical School: Medicine; Concord Clinical School: Medicine; Central Clinical School: Surgery; Concord Clinical School: Medicine; Concord Clinical School: Asbestos Disease Research Institute; Concord Clinical School: ANZAC Research InstituteAn RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma, British Journal of Cancer, vol.110, 2, 2014,pp 510-519
2017Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation studyBailey, Dale; Boyer, Michael; Chrzanowska, Agata; Clarke, Stephen; Cooper, Wendy Anne; Fulham, Michael; Huynh, Yen; Kao, Steven; Kritharides, Leonard; Linton, Anthony; Pavlakis, Nick; Reid, Glen; van Zandwijk, Nico; Brahmbhatt, Himanshu; MacDiarmid, Jennifer; Pattison, Scott; Ridley, Lloyd; Medical Imaging and Radiation Sciences; Central Clinical School: Medicine; School of Public Health: Public Health; Northern Clinical School: Kolling Institute; Central Clinical School: Medicine; Information Technologies; Concord Clinical School: Medicine; Central Clinical School: Medicine; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: Medicine; Northern Clinical School: Medicine; Concord Clinical School: Medicine; Concord Clinical School: MedicineSafety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study, The Lancet Oncology, vol.18, 10, 2017,pp 1386-1396
2012The ticking time-bomb of asbestos: Its insidious role in the development of malignant mesotheliomaClarke, Stephen; Linton, Anthony; van Zandwijk, Nico; Vardy, Janette; Concord Clinical School: Medicine; Concord Clinical School: Medicine; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: MedicineThe ticking time-bomb of asbestos: Its insidious role in the development of malignant mesothelioma, Critical Reviews in Oncology / Hematology (online), vol.84, 2, 2012,pp 200-212
2017Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural MesotheliomaBoyer, Michael; Cheng, Yuen Yee; Cooper, Wendy Anne; Kao, Steven; Kirschner, Michaela; Madore, Jason; McCaughan, Brian; Reid, Glen; Scolyer, Richard; van Zandwijk, Nico; Williams, Marissa; Klebe, Sonja; Linton, Anthony; Lum, Trina; Sarun, Kadir; Central Clinical School: Medicine; Concord Clinical School: ANZAC Research Institute; Central Clinical School: Medicine; Central Clinical School: Medicine; Concord Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Surgery; Concord Clinical School: Medicine; Central Clinical School: Pathology; Concord Clinical School: Medicine; Concord Clinical School: Asbestos Disease Research InstituteTumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma, Journal of Thoracic Oncology, vol.12, 9, 2017,pp 1421-1433